Answers are grounded in this paper and cite their sources.
Recent evidence from randomized trials demonstrates that colchicine can reduce the risk of major adverse cardiovascular events (MACE) in patients with coronary artery disease. Colchicine's effect on lower-extremity peripheral artery disease (PAD) is not known.
No takes yet. Share an insight, caveat, or question.
Heindel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: